Literature DB >> 26438630

Definition, epidemiology and registries of pulmonary hypertension.

R Awdish1, H Cajigas2.   

Abstract

Pulmonary arterial hypertension (PAH) is a subcategory of pulmonary hypertension (PH) that comprises a group of disorders with similar pulmonary vascular pathology. Though PH is common, the estimated incidence of IPAH is 1-3 cases per million, making it a rare disease. The hemodynamic definition of PAH is a mean pulmonary artery pressure at rest >OR = 25 mm Hg in the presence of a pulmonary capillary wedge pressure <OR = 15 mmHg with pulmonary vascular resistance (PVR) greater than 3 WU. Specific maneuvers during right heart catheterization can be utilized to disclose vasoreactivity and heart failure with preserved ejection fraction, which have implications for management. The inherent complexity in studying a rare disease that exhibits clinical overlap with a common syndrome necessitated the creation of registries. These registries have been indispensable in the characterization and mapping of the natural history of the disease. Equations and risk calculators derived from registries have given clinicians a basis for risk stratification and prognostication. The sequential accumulation of data since the registries began in the 1980s allows for comparisons to be made. Patients who are differentiated by treatment eras and environments can be contrasted. Variability among inclusion criteria similarly allows for comparisons of these subpopulations. This article provides an overview of available registries, highlights insights provided by each and discusses key issues around the interpretation and extrapolation of data from PAH registries. Registries have allowed us to appreciate the improvement in survival afforded by modern therapy and enhanced detection of this disease. Moving forward, a more global approach to registries is needed, as is enhanced collaboration and centralization.

Entities:  

Keywords:  COMPERA; Definition; Epidemiology; French registry; Incidence; Natural history of PAH; Prevalence; Pulmonary arterial hypertension; REVEAL; Registries; Risk equation; Risk-score calculator; US-NIH

Mesh:

Year:  2016        PMID: 26438630     DOI: 10.1007/s10741-015-9510-y

Source DB:  PubMed          Journal:  Heart Fail Rev        ISSN: 1382-4147            Impact factor:   4.214


  26 in total

1.  Baseline characteristics and follow-up in patients with normal haemodynamics versus borderline mean pulmonary arterial pressure in systemic sclerosis: results from the PHAROS registry.

Authors:  Sangmee Bae; Rajeev Saggar; Marcy B Bolster; Lorinda Chung; Mary Ellen Csuka; Chris Derk; Robyn Domsic; Aryeh Fischer; Tracy Frech; Avram Goldberg; Monique Hinchcliff; Vivien Hsu; Laura Hummers; Elena Schiopu; Maureen D Mayes; Vallerie McLaughlin; Jerry Molitor; Nausheen Naz; Daniel E Furst; Paul Maranian; Virginia Steen; Dinesh Khanna
Journal:  Ann Rheum Dis       Date:  2012-02-02       Impact factor: 19.103

2.  Design of the REVEAL registry for US patients with pulmonary arterial hypertension.

Authors:  Michael D McGoon; Abby Krichman; Harrison W Farber; Robyn J Barst; Gary E Raskob; Theodore G Liou; Dave P Miller; Kathy Feldkircher; Scott Giles
Journal:  Mayo Clin Proc       Date:  2008-08       Impact factor: 7.616

Review 3.  Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review.

Authors:  G Kovacs; A Berghold; S Scheidl; H Olschewski
Journal:  Eur Respir J       Date:  2009-03-26       Impact factor: 16.671

Review 4.  Diagnosis and assessment of pulmonary arterial hypertension.

Authors:  David B Badesch; Hunter C Champion; Miguel Angel Gomez Sanchez; Marius M Hoeper; James E Loyd; Alessandra Manes; Michael McGoon; Robert Naeije; Horst Olschewski; Ronald J Oudiz; Adam Torbicki
Journal:  J Am Coll Cardiol       Date:  2009-06-30       Impact factor: 24.094

5.  The International Primary Pulmonary Hypertension Study (IPPHS).

Authors: 
Journal:  Chest       Date:  1994-02       Impact factor: 9.410

6.  Clinical characterization and survival of patients with borderline elevation in pulmonary artery pressure.

Authors:  Gustavo A Heresi; Omar A Minai; Adriano R Tonelli; Jeffrey P Hammel; Samar Farha; Joseph G Parambil; Raed A Dweik
Journal:  Pulm Circ       Date:  2013-12       Impact factor: 3.017

Review 7.  Definitions and diagnosis of pulmonary hypertension.

Authors:  Marius M Hoeper; Harm Jan Bogaard; Robin Condliffe; Robert Frantz; Dinesh Khanna; Marcin Kurzyna; David Langleben; Alessandra Manes; Toru Satoh; Fernando Torres; Martin R Wilkins; David B Badesch
Journal:  J Am Coll Cardiol       Date:  2013-12-24       Impact factor: 24.094

8.  Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era.

Authors:  Marc Humbert; Olivier Sitbon; Ari Chaouat; Michèle Bertocchi; Gilbert Habib; Virginie Gressin; Azzedine Yaïci; Emmanuel Weitzenblum; Jean-François Cordier; François Chabot; Claire Dromer; Christophe Pison; Martine Reynaud-Gaubert; Alain Haloun; Marcel Laurent; Eric Hachulla; Vincent Cottin; Bruno Degano; Xavier Jaïs; David Montani; Rogério Souza; Gérald Simonneau
Journal:  Circulation       Date:  2010-06-28       Impact factor: 29.690

9.  Schistosomiasis associated pulmonary hypertension.

Authors:  A Hovnanian; S Hoette; C J C Fernandes; C Jardim; R Souza
Journal:  Int J Clin Pract Suppl       Date:  2010-01

10.  Primary pulmonary hypertension. A national prospective study.

Authors:  S Rich; D R Dantzker; S M Ayres; E H Bergofsky; B H Brundage; K M Detre; A P Fishman; R M Goldring; B M Groves; S K Koerner
Journal:  Ann Intern Med       Date:  1987-08       Impact factor: 25.391

View more
  9 in total

1.  Baseline and Serial Brain Natriuretic Peptide Level Predicts 5-Year Overall Survival in Patients With Pulmonary Arterial Hypertension: Data From the REVEAL Registry.

Authors:  Robert P Frantz; Harrison W Farber; David B Badesch; C Greg Elliott; Adaani E Frost; Michael D McGoon; Carol Zhao; David R Mink; Mona Selej; Raymond L Benza
Journal:  Chest       Date:  2018-01-31       Impact factor: 9.410

2.  Prevalence, incidence, and survival of pulmonary arterial hypertension: A systematic review for the global burden of disease 2020 study.

Authors:  Sophia Emmons-Bell; Catherine Johnson; Alexandra Boon-Dooley; Paul A Corris; Peter J Leary; Stuart Rich; Magdi Yacoub; Gregory A Roth
Journal:  Pulm Circ       Date:  2022-01-18       Impact factor: 2.886

3.  PulmoCor: national registry for pulmonary hypertension.

Authors:  M C Post; A P Van Dijk; E S Hoendermis; H J Bogaard; V Van Empel; K A Boomars
Journal:  Neth Heart J       Date:  2016-04-05       Impact factor: 2.380

4.  Retrospective observational analysis of hospital discharge database to characterize primary pulmonary hypertension and its outcomes in Spain from 2004 to 2015.

Authors:  Javier de-Miguel-Díez; Ana Lopez-de-Andres; Valentin Hernandez-Barrera; Isabel Jimenez-Trujillo; Manuel Mendez-Bailon; Jose M de Miguel-Yanes; Nuria Muñoz-Rivas; Martin Romero-Maroto; Rodrigo Jimenez-Garcia
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

5.  Characterization of Patients with Pulmonary Arterial Hypertension: Data from the Polish Registry of Pulmonary Hypertension (BNP-PL).

Authors:  Grzegorz Kopeć; Marcin Kurzyna; Ewa Mroczek; Łukasz Chrzanowski; Tatiana Mularek-Kubzdela; Ilona Skoczylas; Beata Kuśmierczyk; Piotr Pruszczyk; Piotr Błaszczak; Ewa Lewicka; Danuta Karasek; Katarzyna Mizia-Stec; Michał Tomaszewski; Wojciech Jacheć; Katarzyna Ptaszyńska-Kopczyńska; Małgorzata Peregud-Pogorzelska; Anna Doboszyńska; Agnieszka Pawlak; Zbigniew Gąsior; Wiesława Zabłocka; Robert Ryczek; Katarzyna Widejko-Pietkiewicz; Marcin Waligóra; Szymon Darocha; Michał Furdal; Michał Ciurzyński; Jarosław D Kasprzak; Marek Grabka; Karol Kamiński; Piotr Hoffman; Piotr Podolec; Adam Torbicki
Journal:  J Clin Med       Date:  2020-01-08       Impact factor: 4.241

6.  Carbon Monoxide Diffusion Capacity as a Severity Marker in Pulmonary Hypertension.

Authors:  Eleni Diamanti; Vasiliki Karava; Patrick Yerly; John David Aubert
Journal:  J Clin Med       Date:  2021-12-27       Impact factor: 4.241

7.  The impact of the COVID-19 pandemic on the care of pulmonary hypertension patients outside the Hubei province in China.

Authors:  Yuqin Chen; Bihua Zhong; Qian Jiang; Yilin Chen; Wenjun He; Ning Lai; Dansha Zhou; Jiahao He; Yiting Yao; Yi Shen; Juan Li; Jianuo Yang; Zhe Zhang; Ran Ma; Jian Wang; Chunli Liu
Journal:  Pulm Circ       Date:  2022-07-01       Impact factor: 2.886

8.  Changes in REVEAL risk score in patients with pulmonary arterial hypertension treated with macitentan in clinical practice: results from the PRACMA study.

Authors:  Pilar Escribano-Subias; Raquel López; Luis Almenar; María Lázaro; Ian Forn; Anna Torrent; Isabel Blanco; Joan Albert Barberà
Journal:  BMC Pulm Med       Date:  2020-06-02       Impact factor: 3.317

9.  High geographic prevalence of pulmonary artery hypertension: associations with ethnicity, drug use, and altitude.

Authors:  Jason Dubroff; Lana Melendres; Yan Lin; Daniel Raley Beene; Loren Ketai
Journal:  Pulm Circ       Date:  2020-02-04       Impact factor: 3.017

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.